In recent trading session, Outlook Therapeutics Inc (NASDAQ:OTLK) saw 0.56 million shares changing hands at last check today with its beta currently measuring 0.58. Company’s recent per share price level of $2.14 trading at $0.12 or 6.19% at last check today assigns it a market valuation of $68.60M. That most recent trading price of OTLK’s stock is at a discount of -500.47% from its 52-week high price of $12.85 and is indicating a premium of 59.35% from its 52-week low price of $0.87. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.94 million shares which gives us an average trading volume of 2.05 million if we extend that period to 3-months.
For Outlook Therapeutics Inc (OTLK), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.40. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.52 in the current quarter.
Outlook Therapeutics Inc (NASDAQ:OTLK) trade information
Upright in the green today for gaining 6.19%, in the last five days OTLK remained trading in the green while hitting it’s week-highest on Friday, 01/31/25 when the stock touched $2.14 price level, adding 5.31% to its value on the day. Outlook Therapeutics Inc’s shares saw a change of 13.49% in year-to-date performance and have moved 7.79% in past 5-day. Outlook Therapeutics Inc (NASDAQ:OTLK) showed a performance of 15.32% in past 30-days. Number of shares sold short was 4.13 million shares which calculate 1.26 days to cover the short interests.
Outlook Therapeutics Inc (OTLK) estimates and forecasts
Statistics highlight that Outlook Therapeutics Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -72.32% of value to its shares in past 6 months, showing an annual growth rate of 43.61% while that of industry is 16.00. Apart from that, the company came raising its revenue forecast for fiscal year 2025.
And 5 analysts are in estimates of company making revenue of 702.6k in the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -15.45% during past 5 years.
Outlook Therapeutics Inc (NASDAQ:OTLK)’s Major holders
Insiders are in possession of 35.58% of company’s total shares while institution are holding 35.63 percent of that, with stock having share float percentage of 55.31%. Investors also watch the number of corporate investors in a company very closely, which is 35.63% institutions for Outlook Therapeutics Inc that are currently holding shares of the company. ROSALIND ADVISORS, INC. is the top institutional holder at OTLK for having 0.45 million shares of worth $3.32 million. And as of 2024-06-30, it was holding 3.1534 of the company’s outstanding shares.
On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024, the former fund manager was holding 442.51 shares of worth $0.93 million or 1.38% of the total outstanding shares. The later fund manager was in possession of 400.51 shares on Nov 30, 2024, making its stake of worth around $0.84 million in the company or a holder of 1.25% of company’s stock.
